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The menopause transition (MT) is a period of rapid bone loss and has been proposed to be a 
time-limited window for early intervention to prevent permanent microarchitectural damage and 
reduce the risk of subsequent fracture. To intervene early, however, we first need to be able to 
determine whether menopause-related bone loss is about to begin, in advance of substantial bone 
loss. The objective of this study was, therefore, to assess whether urinary N-telopeptide (U-NTX) 
in pre- or early perimenopause can predict the onset of menopause-related bone loss. Repeated 
U-NTX measurements were obtained during pre- and early perimenopause in 1243 participants 
from the Study of Women’s Health Across the Nation (SWAN). We examined the ability of U-
NTX to predict the onset of significant menopause-related bone loss (categorical outcome, yes 
versus no) at the lumbar spine (LS) and femoral neck (FN), defined as annualized bone mineral 
density (BMD) decline at a rate faster than the smallest detectable change in BMD over the 3 to 
4 years from the time of U-NTX measurement. Adjusting for age, race/ethnicity, body mass 
index, urine collection time, starting BMD, and study site in multivariable, modified Poisson 
regression, every standard deviation increment in U-NTX, measured at baseline in early 
perimenopausal women, was associated with an 18% and 22% greater risk of significant bone 
loss at the LS (p = 0.003) and FN (p = 0.003), respectively. The area under the receiver-operator 
curve for predicting LS and FN bone loss was 0.72 and 0.72, respectively. In mixed-effects 
analysis of all repeated measures of early perimenopausal U-NTX over follow-up, U-NTX 
predicted onset of bone loss at the LS (p = 0.002) but not at the FN. We conclude that U-NTX 
can be used early in the MT to determine if a woman is about to experience significant LS bone 
loss before there has been substantial skeletal deterioration. © 2018 American Society for Bone 
and Mineral Research.  
KEY WORDS: MENOPAUSE; BIOCHEMICAL MARKERS OF BONE TURNOVER; 
OSTEOPOROSIS; DXA; GENERAL POPULATION STUDIES</KWD> 
Introduction 
Osteoporosis is characterized by skeletal fragility resulting from decreased bone mineral density 
(BMD) and impaired bone quality.(1) In women, menopause transition (MT)-related BMD 
decline accelerates 1 year before the final menstrual period (FMP) and slows slightly in 
postmenopause.(2) This loss in BMD during the menopause transition (MT) is accompanied by 
damage to trabecular microarchictecture that may increase fracture risk.(3,4) Within the first 









critical period to intervene to prevent rapid bone loss and permanent microarchitectural 
deterioration.(7) To do so, however, we first need to be able to recognize when women are about 
to lose a significant amount of bone so that they can be targeted for intervention before 
substantial loss. Although we know that MT-related BMD decline accelerates around 1 year 
before the FMP,(2) an FMP-based approach to recognizing the onset of significant bone loss is 
not feasible in real time. This is because the onset time point can only be determined 
retrospectively 1 year after the FMP has passed, when the FMP can be recognized and dated.  
MT-related BMD decline is driven by an increase in bone resorption.(8) Prior studies have 
reported that the bone resorption marker, urinary N-terminal telopeptide of type I collagen (U-
NTX), begins to increase less than 1 year before the onset of MT-related bone loss.(2,8) We, 
therefore, designed this study to answer the following two questions: 1) Can U-NTX measured 
when a woman is in her mid-40s to early 50s and either premenopausal (ie, still having regular 
menstrual cycles) or in early perimenopause (ie, starting to have irregular menstrual cycles but 
with no gaps of 3 months or longer) be used to determine if she is about to begin to experience 
significant MT-related bone loss; and 2) Is the ability of U-NTX to predict the onset of 
significant MT-related bone loss different when measured in premenopause versus early 
perimenopause.  
Answering the first question will tell us if age alone should trigger measurement of bone 
resorption markers for determining the onset of MT-related bone loss, and the second will tell us 
if waiting for early perimenopause to measure bone resorption markers will improve the 
determination and be more efficient. We used data from the Study of Women’s Health Across 
the Nation (SWAN), a longitudinal study of the MT in a multi-ethnic, community-based cohort 
of participants with annual measurements of U-NTX and BMD, to answer both questions.  
Materials and Methods 
SWAN is a multi-center, community-based, longitudinal cohort study of the MT. At baseline, 
participants were aged 42 to 52 years, premenopausal (menstruating 3 months before screening 
without change in menstrual regularity in the past year) or early perimenopausal (menstruating 3 
months before screening with decreased regularity in the past year), had an intact uterus with one 
or two ovaries, were not pregnant or lactating, and were not taking sex steroid hormones. The 
entire SWAN cohort included 3302 participants from seven sites: Boston, MA; Chicago, IL; 









Cohort included 2413 participants from five sites (the Chicago and Newark sites did not perform 
bone assessments). Among SWAN Bone Cohort participants, the bone resorption marker, U-
NTX, was measured at baseline and annually thereafter until the eighth annual follow-up visit. 
BMD was measured at baseline and annually thereafter. Participants gave written informed 
consent, and sites obtained institutional review board approval.  
Study sample 
Of the 2413 bone cohort participants, 70 women were excluded because they did not have U-
NTX measurement at their baseline visit. An additional 1100 women were excluded because we 
could not determine whether they had lost bone over the next 3 to 4 years, either because they 
were missing baseline or follow-up BMD data or because they initiated bone-modifying 
medications between the two DXA scans. This left us with a base study sample of 1243 women.  
Predictors 
U-NTX was measured from a non-first voided urine obtained before 10 a.m. Specimens were 
stored at –20°C to –80°C at local sites for up to 1 month until shipment to the Central Lab 
(Medical Research Laboratories, Highland Heights, KY, USA). At the Central Lab, all samples 
were stored at –80°C. U-NTX was measured using the Osteomark competitive inhibition enzyme 
immunoassay (nM BCE; Osteomark, Ostex International Inc., Seattle, WA, SUA; interassay 
coefficient of variation [CV] <12%; intra-assay CV <8%). Urinary creatinine was measured 
using the Cobas Mira autoanalyzer (mM; Horiba ABX, Montpellier, France; interassay CV 
4.1%; intra-assay CV 0.6%). U-NTX was normalized by urinary creatinine and expressed in nM 
BCE/mM Cr.(8,9)  
Outcomes 
Lumbar spine (LS) and femoral neck (FN) BMD were measured by dual-energy X-ray 
absorptiometry (DXA; Hologic [Waltham, MA, USA] QDR 2000 at Pittsburgh and Oakland 
sites; Hologic QDR 4500A at Boston, Los Angeles, and Michigan sites). Cross-site calibration 
was performed by circulating an anthropomorphic spine phantom. Standard quality-control 
phantom scans were performed before each BMD measurement session. These were used to 
adjust for machine drift when necessary. The Pittsburgh and Oakland sites upgraded from the 
2000 to 4500A models at follow-up visit 8. These sites scanned 40 women on both their old and 
new machines to develop cross-calibration regression equations.(2,9) 









NTX measurement to the first BMD measurement 3 to 4 years later, divided by the number of 
intervening years. We calculated BMD decline over a 3- to 4-year period to allow the change in 
BMD to be sufficiently large to exceed the precision error in DXA measurements.(10,11) We 
determined that a woman was losing significant bone (categorical outcome, yes/no) if the 
annualized BMD decline rate was faster than a prespecified threshold. We used two different 
BMD decline rate thresholds to infer significant bone loss. The first was the site-specific least 
significant change (LSC) in BMD divided by the median number of intervening years between 
BMD measurements in the study sample. The LSC for a measure depends on the precision error 
in its measurement and is the smallest amount of change that would be statistically significantly 
different from no change at 2-sided type I error (alpha) of 5%.(10,12,13) The LSC is recommended 
for defining whether a true physiologic change in BMD has occurred in clinical practice and is 
calculated as 2.77 times the CV for the measurement.(10) In SWAN, each of the five Bone Cohort 
sites performed duplicate BMD measurements at the LS and FN in five women, with complete 
repositioning (25 duplicate measurements in total). From these measurements, the short-term in 
vivo precision error was calculated using the root mean square SD approach recommended by 
the International Society for Clinical Densitometry. Because the CV for LS and FN BMD 
measurements in SWAN were 1.4% and 2.2%, respectively,(2) and the median number of years 
between BMD measurement was 3.2 in the study sample, the LSC-based BMD decline rate 
threshold was 1.23% per year for LS and 1.93% per year for FN. The second threshold for 
detecting significant bone loss was based on the distribution of BMD change rates in SWAN 
participants who were 5 or more years before the FMP and can be presumed to have relatively 
stable BMD (stable group).(2) After calculating the ongoing rates of change in BMD in these 
women, we categorized a rate of change in BMD that was lower (more negative) than the 5th 
percentile of the site-specific distribution as significant bone loss (–1.59% per year for LS, –
1.86% per year for FN).  
Covariates 
Body mass index (BMI) was calculated from weight and height measurements (BMI = weight in 
kilograms / [height in meters]2). Menopause transition status was determined by menstrual 
bleeding patterns. Premenopause was defined as no change in menstrual regularity in the past 
year. Early perimenopause was defined as decreased regularity in menstrual bleeding but with no 










The first set of analyses were designed to answer whether U-NTX in pre- or early 
perimenopausal women, 42 to 52 years old, can help infer if a woman will begin to experience 
significant bone loss in the next 3 to 4 years. We used multivariable modified Poisson regression 
with U-NTX at SWAN baseline as primary predictor and significant bone loss (yes/no) from 
time of U-NTX measurement to 3 to 4 years later as outcome and adjusted for MT stage (pre- 
versus early perimenopause), age, race/ethnicity (white, African American, Chinese, Japanese), 
BMI, urine collection time (to account for diurnal variation in bone turnover markers), starting 
BMD, and study site as covariates and robust estimation of standard error.(14) We used modified 
Poisson regression instead of logistic regression because bone loss is not a rare outcome in this 
group and because the former approach is more robust to model misspecification.(13) Separate 
analyses were conducted for LS bone loss and FN bone loss, each defined using two BMD 
decline rate thresholds (as described above).  
To answer whether the ability of U-NTX to predict the onset of significant MT-related bone loss 
is different when measured in premenopause versus early perimenopause, we first repeated the 
above analyses after stratifying the study sample by MT stage at SWAN baseline (720 
premenopausal, 523 early perimenopausal). Because our ability to detect the hypothesized 
associations could be limited by the reduced sample size in each stratum, we also conducted 
repeated measures, mixed-effects analyses using all premenopausal and early perimenopausal U-
NTX measurements (from baseline and all follow-up SWAN visits). We used mixed-effects, 
modified Poisson regression to separately model premenopausal U-NTX and early 
perimenopausal U-NTX as predictors of significant bone loss over the next 3 to 4 years, while 
accounting for within-woman correlations between repeated measures and adjusting for the same 
covariates as in the baseline analysis (age, race/ethnicity, BMI, urine collection time, starting 
BMD, and study site). Time-varying covariates (age, BMI, starting BMD, and urine collection 
time) were assessed at the time of U-NTX measurement. As in the baseline analyses, only the 
current level of U-NTX was used to predict bone loss; prior measurements were not incorporated 
in the prediction models. The repeated measures analysis of premenopausal U-NTX used 1386 
observations from 720 women who were in premenopause at SWAN baseline. For the repeated 
measures analysis of early perimenopausal U-NTX, we had 2877 observations from 1033 









510 women who were premenopausal at baseline and had at least one SWAN follow-up visit in 
early perimenopause.  
For both sets of analyses described above, we conducted parallel sensitivity analyses using the 
same statistical approach, primary predictors, and covariates, but with significant bone loss 
(yes/no) defined as a BMD decline rate that was faster than the site-specific LSC expressed as 
absolute change in BMD (instead of percent change in BMD). We performed these sensitivity 
analyses because a given absolute change in BMD will correspond to different percent changes 
depending on starting BMD. In SWAN, the CVs for LS and FN BMD measurements in absolute 
terms were 0.012 and 0.014 g/cm2, respectively.(2) With the median number of years between 
BMD measurements in the study sample being 3.2, the absolute LSC-based BMD decline rate 
thresholds were thus 0.016 (LS) and 0.017 (FN) g/cm2 per year. 
Results 
Participant characteristics at SWAN baseline 
In the baseline U-NTX analytic sample, mean age was 46.0 years (range 42.0 to 52.8 years). 
Nearly half were white, 17.8% African American, 14.7% Chinese, and 6.4% Japanese. The 
majority (57.9%) were premenopausal (Table 1). {TBL 1} Mean decline in BMD was faster in 
the LS than in the FN, and more women experienced significant bone loss in the LS over the 
next 3 to 4 years from SWAN baseline than in the FN, regardless of which BMD decline rate 
threshold was used to categorize the onset of bone loss (LSC-based or distribution-based).  
U-NTX at baseline was normally distributed (median U-NTX was 31.5 BCE/mM Cr, and the 
interquartile range [IQR] was from 23.2 to 40.8 BCE/mM Cr). Mean U-NTX at baseline was 
similar in early peri- and premenopausal women (34.1 versus 33.0 BCE/mM Cr, p = 0.2). 
However, the SD of U-NTX was larger in early perimenopause (Table 1). Consistent with this, 
BMD declined faster in early perimenopausal than in premenopausal women over the next 3 to 4 
years at both the LS (mean change –0.6% versus –0.2% per year, p < 0.001) and FN (mean 
change –0.4 versus –0.1% per year, p < 0.001). A greater proportion of early perimenopausal 
than premenopausal women was therefore categorized as losing significant bone using either 
threshold: 28.3 versus 15.1% (p < 0.001) in the LS, 10.8 versus 5.0% (p < 0.001) in the FN using 
LSC-based thresholds, and 21.4 versus 11.0% in the LS (p < 0.001), 12.3 versus 5.5% in the FN 
(p < 0.001) using distribution-based thresholds (Figs.1 and 2). {FIG1}{FIG2} 









Greater U-NTX at SWAN baseline (when participants were aged 42 to 52 years and pre- or early 
perimenopause) was independently associated with greater risk of bone loss onset over the next 3 
to 4 years, after adjusting for MT stage, age, BMI, race/ethnicity, urine collection time, starting 
BMD, and study site in modified Poisson regression (Table 2). {TBL 2} Each standard deviation 
(SD) increment in U-NTX was associated with a 12% increment in risk of significant LS bone 
loss (p = 0.03) defined as LS BMD decline faster than the LSC-based threshold (1.23% per 
year), or 19% increment (p = 0.04) using the distribution-based threshold (1.59% per year). In 
contrast, baseline U-NTX was not significantly associated with risk of significant FN bone loss 
over the next 3 to 4 years for loss defined with either the LSC- or distribution-based thresholds 
(Table 2).  
Age, MT stage, race/ethnicity, and BMI also were independently associated with the probability 
of significant bone loss (data not shown). Early perimenopausal women were 49% and 50% 
more likely to be losing significant bone at the LS than premenopausal women (p < 0.01) using 
LSC- and distribution-based thresholds for bone loss, after controlling for U-NTX and the other 
covariates. The ability of U-NTX (in combination with age, MT stage, race/ethnicity, and BMI) 
to identify women who began losing significant bone at the LS during the next 3 to 4 years (as 
measured by the area under the receiver operating characteristic [ROC] curve [AUC]) was 0.72 
(for loss defined using the LSC-based threshold) and 0.74 (for loss defined using the 
distribution-based threshold). 
In analyses stratified by MT stage, baseline U-NTX measured in women who were 
premenopausal at SWAN baseline did not predict onset of significant bone loss over the next 3 to 
4 years. In contrast, baseline U-NTX measured in women who were early perimenopausal at 
SWAN baseline did strongly predict risk of significant LS (by LSC- [AUC 0.72] and 
distribution-based thresholds [AUC 0.74]) and FN bone loss (LSC-based threshold [AUC 0.72]) 
(Table 2).  
Descriptive statistics for repeated U-NTX measures 
The average number of U-NTX observations in premenopause per participant was 2.1, with 
median of 1 and range of 1 to 7. The average number of observations in early perimenopause per 
participant was 3.8, with median of 4 and range of 1 to 8. A greater proportion of visits in early 
perimenopause were followed by significant LS and FN bone loss compared with visits in 









Repeated measures analysis stratified by MT stage 
In mixed-effects, modified Poisson regression, after adjusting for age, BMI, race/ethnicity, urine 
collection time, starting BMD, and study site, premenopausal U-NTX was not associated with 
risk of onset of significant bone loss over the next 3 to 4 years (Table 4). {TBL 4} In contrast, in 
early perimenopause, greater U-NTX was associated with greater risk of significant LS bone 
loss. Each SD increment in early perimenopausal U-NTX increased risk of bone loss at the LS 
by 7% (p < 0.02) regardless of which BMD decline rate threshold was used to define bone loss. 
The ability of early perimenopausal U-NTX (in combination with age, race/ethnicity, and BMI) 
to identify those who would begin losing bone at the LS (as measured by AUC) was 0.72 (for 
both distribution- and LSC-based thresholds). Given emerging data that the optimal way to 
utilize bone turnover markers is to incorporate them into prediction models that also include 
relevant clinical covariates,(9) we created a “sample” tool that calculates the predicted probability 
of significant LS bone loss over the next 3 to 4 years (using the LSC-based threshold) from user-
specified entries for race/ethnicity, age, BMI, and U-NTX (Supplemental Data). Thus, for a 
white female who is 47 years of age, has a BMI of 22, and a U-NTX of 32 BCE/mM Cr, the 
predicted probability of experiencing a significant bone loss at the LS over the next 3 to 4 years 
is 32%. If the same woman has a U-NTX of 65 BCE/mM Cr, the predicted probability would be 
85%. 
Sensitivity analyses 
For each of the analyses described above, we conducted corresponding sensitivity analyses in 
which significant bone loss was defined as a BMD decline rate that was faster than the LSC 
defined as absolute change in BMD per year (0.016 g/cm2 per year for LS and 0.017 g/cm2 per 
year for FN). The proportions of women who were considered to be losing bone at the LS and 
FN using these thresholds were similar to those when the LSC was expressed as percent change 
in BMD per year. The association of U-NTX with significant bone loss was also strongest at the 
LS during early perimenopause (data not shown). 
Discussion 
The objective of this study was to answer two questions: 1) Can U-NTX measured when a 
woman is in her mid-40s to early 50s help determine if she is about to experience significant 
MT-related bone loss; and 2) Is the ability of U-NTX to predict the onset of MT-related bone 









old women with higher levels of U-NTX were more likely to experience significant bone loss at 
the LS over the next 3 to 4 years than same-aged women with lower levels of U-NTX, but this 
association was driven entirely by women in early perimenopause. Premenopausal U-NTX was 
not a predictor of significant bone loss over the next 3 to 4 years, whereas early perimenopausal 
U-NTX did strongly predict bone loss. This was confirmed in repeated measures analyses using 
all premenopausal and early perimenopausal U-NTX measurements from baseline and follow-up 
visits. These repeated measures analyses allow for clinical situations wherein a woman may be 
evaluated anywhere from a few months to several years into the same MT stage. Combining 
early perimenopausal U-NTX with relevant clinical covariates (age, race/ethnicity, and BMI) 
provided good discrimination between women who were more versus less likely to begin losing 
significant bone at the LS over the next 3 to 4 years (AUC >0.7).  
Prior studies have examined the association between BTMs and rates of bone loss (as a 
continuous outcome). The totality of the literature suggests that greater levels of bone resorption 
markers are associated with faster bone loss.(9,15–23) The majority of these studies, however, were 
in women who were postmenopausal.(15,17,19,21) and had already experienced substantial BMD 
decline. In SWAN, we previously demonstrated that higher U-NTX is associated with higher 
rates of BMD decline (continuous outcome) during the MT and early postmenopause.(9) Here, we 
tested the ability of U-NTX, measured early in the MT (ie, in advance of significant bone loss) to 
predict whether a woman would experience significant MT-related bone loss (as a categorical 
outcome) over the next several years in a large, multi-ethnic cohort. Recognizing that a woman is 
about to, or has just begun to, experience significant bone loss is one important consideration 
when deciding whether to initiate interventions to prevent rapid bone loss across the MT.  
Our finding that early perimenopausal U-NTX predicts the onset of MT-related bone loss at the 
LS independent of age suggests that U-NTX provides information about whether significant LS 
bone loss will occur in the next few years, above and beyond chronological age and clinical 
bleeding patterns. MT-related bone loss begins approximately 1 year before the FMP.(2) 
However, clinical bleeding patterns are not useful for predicting how many years a woman is 
from her FMP.(2,24) For example, women can experience anywhere from several months to more 
than 5 years of less predictable menstrual bleeding before having her FMP.(24) In the absence of 
knowledge about how far a woman is from her FMP, U-NTX can be valuable as a physiologic 









similar during pre- and early perimenopause, there were more women in early perimenopause 
who had higher U-NTX levels and were losing significant BMD. 
The combination of early perimenopausal U-NTX, age, race/ethnicity, and BMI (all independent 
predictors of bone loss) also provided good discrimination ability for onset of LS bone loss, as 
suggested by AUC values that exceed 0.7.(25,26) Consistent with the emerging consensus that the 
optimal way to utilize BTMs is to incorporate them into prediction models that also include 
relevant clinical covariates,(9) we created an online tool that calculates the model-predicted 
probability of significant LS bone loss over the next 3 to 4 years from user-specified entries for 
race/ethnicity, age, BMI, and U-NTX (Supplemental Data). We did not include BMD in this tool 
because clinicians may be reluctant to obtain a DXA scan in pre- and early perimenopausal 
women. Before it can be adopted for clinical use, the prediction tool needs to be externally 
validated and should ideally be recreated and validated using serum C-terminal telopeptide of 
type I collagen in serum (S-CTX), which is now recommended as the referent bone resorption 
marker.(27) 
We also report here that significant bone loss was more likely to occur in the LS than in the FN, 
consistent with previous observations that the majority of bone remodeling early in the MT take 
place at trabecular surfaces, of which there are more in the LS than the FN.(28–31) This is also 
consistent with our finding that BMD declined faster at the LS than at the FN, and with previous 
findings that total BMD decline across the MT is greater at the LS than at the FN.(2) These 
differences by site may explain why we found U-NTX to be more strongly associated with bone 
loss at the LS than at the FN. We theorize that the association between U-NTX and onset of FN 
bone loss was weaker because decline in FN BMD early in the MT was not substantially faster 
than the precision of DXA-based FN BMD measurements.(32) Along these lines, it is possible that 
U-NTX would have more strongly predicted significant bone loss at the total hip because of 
lower variability. However, we did not have total hip BMD data in SWAN. 
Our study has several limitations that should be noted. First, S-CTX is now recommended as the 
referent bone resorption marker to use in clinical studies;(27) however, SWAN, which started 20 
years ago, measured U-NTX.(33) Additionally, urinary measures of bone turnover markers are 
criticized for being more variable than serum measures because the need to adjust for urinary 
creatinine introduces an additional source of variability.(34) Given that we were able to detect a 









bone resorption marker with less pre-analytical variability would be better. A second limitation is 
that specimen storage temperature at local sites during the 1-month period before shipment to 
Central Lab was not recorded in SWAN; we were therefore unable to control for this covariate in 
our analyses. Third, although every attempt was made to collect urine samples during the 
follicular phase of the menstrual cycle, this was not always feasible, especially in 
perimenopausal subjects with less predictable menstrual bleeding (up to 90 days between 
cycles). This may have increased the pre-analytical variability of U-NTX measurements.(34) 
Finally, although combining U-NTX with a bone formation marker improves prediction of rate 
of BMD decline,(35) we could not test this approach in this study because we did not have enough 
contemporaneous measures of U-NTX and a bone formation marker in SWAN.  
To conclude, this study confirms that U-NTX measured during early perimenopause is strongly 
associated with the likelihood of bone loss onset at the LS over the next several years, 
independent of age. In addition, its ability to identify women who are about to, or have just 
begun to, experience significant LS bone loss is robust when combined with relevant covariates. 
Future studies will determine the best bone turnover marker or best combination of markers 
needed to determine when women are about to begin rapid loss in bone mass and deterioration in 
microarchitecture before substantial skeletal deterioration. This, in turn, will allow us to test the 
long-term efficacy of early interventions for preventing bone loss and microarchitectural 
damage.(9)  
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Fig. 1. Distribution of rates of change in bone mineral density and thresholds for bone loss 
at the lumbar spine (A) and femoral neck (B) among premenopausal women. BMD decline 
rates to the left of the lines indicating the least significant change- and distribution-based 
thresholds were considered to reflect bone loss. 
Fig. 2. Distribution of rates of change in bone mineral density and thresholds for bone loss at the 
lumbar spine (A) and femoral neck (B) among early perimenopausal women. BMD decline rates 
to the left of the lines indicating the least significant change- and distribution-based thresholds 
were considered to reflect bone loss. A greater proportion of early perimenopausal women were 
considered to be losing bone at the lumbar spine (LS) and femoral neck (FN) compared with 
premenopausal women. 
Table 1. Descriptive Statisticsa for Analytic Sample at Study Baselineb (Study of Women’s 
Health Across the Nation [SWAN]) 
 Pre- and early 
perimenopausal 
subjects 
N = 1243 
Premenopausal 
subjects 




n = 523 
Age (years) 46.3 (2.7) 46.0 (2.6) 46.8 (2.7) 
Race/ethnicity 
African American  250 (20.1) 128 (17.8) 122 (23.3) 
White 621 (50.0) 362 (50.3) 259 (49.5) 
Chinese 175 (14.1) 106 (14.7) 69 (13.2) 
Japanese 197 (15.8) 124 (17.2) 73 (14.0) 
Body mass index (kg/m2) 26.7 (6.5) 26.4 (6.4) 27.1 (6.6) 
N-telopeptide, urine (nM BCE/mM Cr) 33.5 (14.6) 33.0 (13.5) 34.1 (16.0) 
Annualized percent change in bone mineral density 
Lumbar spine (% per year) –0.3 (1.2) –0.2 (1.1) –0.6 (1.3) 
Femoral neck (% per year) –0.2 (1.2) –0.1 (1.2) –0.4 (1.3) 
Losing bone from baseline to 3 to 4 years later (least significant change-based threshold)c 
Lumbar spine  254 (20.6) 107 (15.1) 147 (28.3) 
Femoral neck 92 (7.4) 36 (5.0) 56 (10.8) 
Losing from baseline to 3 to 4 years later (distribution-based threshold)d 
Lumbar spine 189 (15.4) 78 (11.0) 111 (21.4) 
Femoral neck  103 (8.3) 39 (5.5) 64 (12.3) 
aCount (percentage) for categorical variables; mean (standard deviation) for continuous 
variables. All variables (other than rate of change) were measured at SWAN baseline visit.  
bN = 1243. All participants were pre- or early perimenopausal at SWAN baseline. 
cSignificant bone loss (yes/no) using a least significant change-based threshold was defined as an 
annualized lumbar spine (LS) or femoral neck (FN) bone mineral density (BMD) decline rate 
that was faster than 1.23% per year in the LS and 1.93% per year in the FN. 
dSignificant bone loss (yes/no) using a distribution-based threshold was defined as an annualized 
LS or FN BMD decline rate that was faster than 1.59% per year in the LS and 1.86% per year in 










Table 2. Associations Between Urinary N-Telopeptide Measured at SWAN Baseline and 
Significant Bone Loss Over the Next 3 to 4 Years 
 Bone loss by least significant 
change-based thresholda 
Bone loss by distribution-based 
thresholdb 
Full baseline sample (pre- and early perimenopausal women, N = 1243) 
 Mean (95% CI)c p Value Mean (95% CI)c p Value 
Lumbar spine 1.12 (1.02, 1.23) 0.01 1.19 (1.01, 1.39) 0.04 
Femoral neck 1.20 (1.04, 1.37) 0.1 1.14 (0.99, 1.31) 0.05 
Stratified baseline analysis 
Premenopausal women (n = 720) 
 Mean (95% CI)d p Value Mean (95% CI)d p Value 
Lumbar spine 1.06 (0.89, 1.26) 0.4 1.05 (0.86, 1.28) 0.6 
Femoral neck 1.13 (0.79, 1.63) 0.4 1.15 (0.80, 1.64) 0.3 
Early perimenopausal women (n = 523) 
 Mean (95% CI)e p Value Mean (95% CI)e p Value 
Lumbar spine 1.18 (1.06, 1.32) 0.003 1.21 (1.07, 1.38) 0.003 
Femoral neck 1.22 (1.07, 1.41)  0.003 1.15 (0.99, 1.32) 0.05 
aSignificant bone loss (yes/no) using a least significant change-based threshold was defined as an 
annualized lumbar spine (LS) or femoral neck (FN) bone mineral density (BMD) decline rate 
that was faster than 1.23% per year in LS and 1.93% per year in the FN. 
bSignificant bone loss (yes/no) using a distribution-based threshold was defined as an annualized 
LS or FN BMD decline rate that was faster than 1.59% per year in the LS and 1.86% per year in 
the FN.  
cRisk ratio (95% confidence interval) for significant bone loss (at lumbar spine and femoral 
neck) per standard deviation increment in urinary N-telopeptide (14.6 nM BCE/mM Cr) adjusted 
for age, menopause transition stage, race/ethnicity, body mass index, sample collection time, 
starting BMD, and study site. 
dRisk ratio (95% confidence interval) for significant bone loss (at lumbar spine and femoral 
neck) per standard deviation increment in urinary N-telopeptide (13.5 nM BCE/mM Cr) adjusted 
for age, race/ethnicity, body mass index, sample collection time, starting BMD, and study site. 
eRisk ratio (95% confidence interval) for significant bone loss (at lumbar spine and femoral 
neck) per standard deviation increment in urinary N-telopeptide (15.9 nM BCE/mM Cr) adjusted 
for age, race/ethnicity, body mass index, sample collection time, starting BMD, and study site. 
 
Table 3. Descriptive Statisticsa for Repeated Measures Samples 
 Premenopausal 
subjects 




n = 1033 
877 observations 
Age (years) 46.8 (2.7) 48.6 (2.8) 
Race/ethnicity 
African American  237 (17.1) 522 (18.1) 
White 724 (52.2) 1367 (47.5) 
Chinese 199 (14.3) 432 (15.0) 
Japanese 226 (16.3) 556 (19.3) 









N-telopeptide, urine (nM BCE/mM Cr) 33.3 (16.0) 33.6 (18.2) 
Annualized percent change in bone mineral density 
Lumbar spine (% per year) –0.2 (1.2) –0.9 (1.4) 
Femoral neck (% per /year) –0.2 (1.2) –0.7 (1.4) 
Losing from baseline to 3 to 4 years later (least significant change-based threshold)b 
Lumbar spine 234 (17.0) 1058 (36.9) 
Femoral neck 100 (7.3) 491 (17.2) 
Losing bone from baseline to 3 to 4 years later (distribution-based threshold)c 
Lumbar spine  171 (12.5) 839 (29.3) 
Femoral neck 112 (8.1) 534 (18.7) 
aCount (percentage) for categorical variables; mean (standard deviation) for continuous 
variables.   
bSignificant bone loss (yes/no) using a least significant change-based threshold was defined as an 
annualized lumbar spine (LS) or femoral neck (FN) BMD decline rate that was faster than 1.23% 
per year in the LS and 1.93% per year in the FN. 
cSignificant bone loss (yes/no) using a distribution-based threshold was defined as an annualized 
LS or FN BMD decline rate that was faster than 1.59% per year in the LS and 1.86% per year in 
the FN.  
Table 4. Associationsa Between Urinary N-Telopeptide and Significant Bone Loss Over Next 3 to 
4 Years, Stratified by MT Stage; Repeated Measures Analyses 
 Bone loss by least significant 
change-based thresholdb  
Bone loss by distribution-based 
thresholdc 
Premenopausal observations (n = 720 subjects, 1386 observations) 
 Mean (95% CI)d p Value Mean (95% CI)d p Value 
Lumbar spine bone 
loss 
 
1.03 (0.95, 1.12) 0.4 1.01 (0.92, 1.12) 0.7 
Femoral neck bone 
loss 
 
1.07 (0.93, 1.22) 0.3 1.06 (0.92, 1.20) 0.4 
Early perimenopausal observations (n = 1033 subjects, 2877 observations) 
 Mean (95% CI)e p Value Mean (95% CI)e p Value 
Lumbar spine bone 
loss 
 
1.07 (1.01, 1.13) 0.002 1.07 (1.02, 1.13) 0.02 
Femoral neck bone 
loss 
 
1.07 (0.99, 1.16) 0.07 1.06 (0.99, 1.15) 0.1 
aResults of mixed-effects, modified Poisson regression with robust estimation of standard error, 
using repeated measures of U-NTX and bone loss.  
bSignificant bone loss (yes/no) using a least significant change-based threshold was defined as an 
annualized lumbar spine (LS) or femoral neck (FN) bone mineral density (BMD) decline rate 
that was faster than 1.23% per year in the LS and 1.93% per year in the FN. 
cSignificant bone loss (yes/no) using a distribution-based threshold was defined as an annualized 
LS or FN BMD decline rate that was faster than 1.59% per year in the LS and 1.86% per year in 









dRisk ratio for lumbar spine or femoral neck bone loss (yes/no) per standard deviation increment 
in premenopausal urinary N-telopeptide (16.0 nM BCE/mM Cr) adjusted for age, ethnicity, body 
mass index, sample collection time, starting BMD, and study site. 
eRisk ratio for lumbar spine or femoral neck bone loss (yes/no) per standard deviation increment 
in early perimenopausal urinary N-telopeptide (15.2 nM BCE/mM Cr) adjusted for age, 
ethnicity, body mass index, sample collection time, starting BMD, and study site. 
 

















Figure 2  . 
 
